BETA-ADRENORECEPTORS GENETIC POLYMORPHISM CONNECTION WITH BETA-BLOKER THERAPY EFFICACY IN PATIENTS WITH CARDIOVASCULAR DISORDERS

Abstract

At present it is obvious that genetic peculiarities of patients are the major reason for individual differences in pharmacological responses to (β-adrenoblockers. Furthermore ADRB1 gene polymorphism is responsible for the efficiency of (β-adrenoblockers. Thus, a real prospect exists for an individualized approach to administration of (β-adrenoblockers and selection of dosage based on patient’s genotype, which must undoubtedly increase efficiency of the administered therapy. Reviewfocuses on gene polymorphism responsible for (β-adrenoblockers pharmacodynamics and on the clinical significance of the polymorphism detection to individualize drug therapy based on patient’s genotype.

Keywords

• ADRB1 gene
• adrenoblocker
• adrenoreceptor
• pharmacogenetics
• polymorphism